$ENDV
ENDONOVO THERAPEUTICS, INC. Stock $endv

$endv Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000149315223012553 Filed on April 17, 2023

Income Statement

Concept	2023 Q2	2022 Q4	2022
Revenue	$45.20K	$121.5K	$135.4K
YoY Change	6853.85%	37856.25%	85.14%
Cost Of Revenue		$4.870K	$9.990K
YoY Change		-45.03%	-33.36%
Gross Profit	$45.20K	$116.6K	$125.4K
YoY Change	16828.84%	-1465.22%	115.7%
Gross Profit Margin	100.0%	95.99%	92.62%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$161.7K	$161.7K	$646.9K
YoY Change	0.0%	0.0%	-0.24%
% of Gross Profit	357.81%	138.72%	516.02%
Operating Expenses	$1.177M	$599.6K	$3.390M
YoY Change	-34.6%	64.17%	48.37%
Operating Profit	-$1.131M	-$483.1K	-$3.264M
YoY Change	-37.11%	29.23%	46.61%
Interest Expense	$3.107M	-$12.43M	-$15.35M
YoY Change	-574.92%	-547.78%	1604.38%
% of Operating Profit
Other Income/Expense, Net	$3.195M	-$16.39K	-$15.21M
YoY Change	-539.24%
Pretax Income	$2.064M	-$12.93M	-$18.47M
YoY Change	-181.69%	-639.66%	495.02%
Income Tax
% Of Pretax Income
Net Earnings	$2.064M	-$12.93M	-$18.47M
YoY Change	-181.69%	-639.66%	495.02%
Net Earnings / Revenue	4565.62%	-10647.24%	-13649.17%
Basic Earnings Per Share	$0.00		-$0.13
Diluted Earnings Per Share	-$0.01	-$0.07	-$0.13
COMMON SHARES
Basic Shares Outstanding	270.3M shares	194.3M shares	139.2M shares
Diluted Shares Outstanding	1.351B shares

Balance Sheet

Concept	2023 Q2	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$32.60K	$100.00	$100.00
YoY Change		-99.88%	-99.88%
Cash & Equivalents	$32.60K	$98.00
Short-Term Investments
Other Short-Term Assets	$40.23K	$15.72K	$15.72K
YoY Change	704.6%	96.99%	96.99%
Inventory
Prepaid Expenses
Receivables			$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$72.83K	$15.82K	$15.82K
YoY Change	1125.11%	-83.32%	-83.32%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$942.0K	$1.265M	$1.265M
YoY Change	-40.71%	-33.83%	-33.83%
TOTAL ASSETS
Total Short-Term Assets	$72.83K	$15.82K	$15.82K
Total Long-Term Assets	$942.0K	$1.265M	$1.265M
Total Assets	$1.015M	$1.281M	$1.281M
YoY Change	-36.37%	-36.17%	-36.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.449M	$884.2K	$884.2K
YoY Change	84.34%	34.28%	34.28%
Accrued Expenses	$8.758M	$7.985M	$7.985M
YoY Change	20.91%	24.38%	24.38%
Deferred Revenue
YoY Change
Short-Term Debt	$7.027M	$7.153M	$7.153M
YoY Change	-4.48%	-0.39%	-0.39%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$23.14M	$33.38M	$33.38M
YoY Change	11.91%	88.58%	88.58%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$79.83K	$79.83K	$79.83K
YoY Change	0.0%	-0.01%	0.0%
Total Long-Term Liabilities	$79.83K	$79.83K	$79.83K
YoY Change	0.0%	-0.01%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.14M	$33.38M	$33.38M
Total Long-Term Liabilities	$79.83K	$79.83K	$79.83K
Total Liabilities	$23.22M	$33.46M	$33.46M
YoY Change	11.86%	88.18%	88.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.90M	-$75.10M
YoY Change	7.33%	33.05%
Common Stock	$27.88K	$21.32K
YoY Change	85.35%	186.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$22.20M	-$32.18M	-$32.18M
YoY Change
Total Liabilities & Shareholders Equity	$1.015M	$1.281M	$1.281M
YoY Change	-36.37%	-36.17%	-36.17%

Cashflow Statement

Concept	2023 Q2	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$2.064M	-$12.93M	-$18.47M
YoY Change	-181.69%	-639.66%	495.02%
Depreciation, Depletion And Amortization	$161.7K	$161.7K	$646.9K
YoY Change	0.0%	0.0%	-0.24%
Cash From Operating Activities	-$165.8K	-$225.5K	-$700.0K
YoY Change	-19.69%	-42.36%	-29.05%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$142.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	187.5K	202.5K	$593.0K
YoY Change	27.99%	-57.05%	-44.01%
NET CHANGE
Cash From Operating Activities	-165.8K	-225.5K	-$700.0K
Cash From Investing Activities
Cash From Financing Activities	187.5K	202.5K	$593.0K
Net Change In Cash	21.66K	-23.04K	-$85.84K
YoY Change	-136.11%	-128.72%
FREE CASH FLOW
Cash From Operating Activities	-$165.8K	-$225.5K	-$700.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001528172
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	ENDV	Inducement Loss Related To Conversion Of Preferred Stock InducementLossRelatedToConversionOfPreferredStock		usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	ENDV	Original Debt Discount On Convertible Notes OriginalDebtDiscountOnConvertibleNotes		usd
CY2022	ENDV	Issuance Of Common Stock To Settle Debt IssuanceOfCommonStockToSettleDebt		usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited		usd
CY2021	us-gaap	Stock Granted During Period Value Sharebased Compensation Forfeited StockGrantedDuringPeriodValueSharebasedCompensationForfeited		usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-55453
CY2022	dei	Entity Registrant Name EntityRegistrantName	ENDONOVO THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2552528
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	6320 Canoga Avenue
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	15th Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Woodland Hills
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91367
CY2022	dei	City Area Code CityAreaCode	(800)
CY2022	dei	Local Phone Number LocalPhoneNumber	489-4774
CY2022	dei	Security12g Title Security12gTitle	Common stock, par value $0.0001
CY2022	dei	Trading Symbol TradingSymbol	ENDV
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1128567	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	270285405	shares
CY2022	dei	Auditor Firm AuditorFirmId	468
CY2022	dei	Auditor Name AuditorName	Rose, Snyder & Jacobs LLP
CY2022	dei	Auditor Location AuditorLocation	Encino, CA
CY2022Q4	us-gaap	Cash Cash	98	usd
CY2021Q4	us-gaap	Cash Cash	85936	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	944	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15724	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7975	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	15822	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	94855	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1265444	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1912356	usd
CY2022Q4	us-gaap	Assets Assets	1281266	usd
CY2021Q4	us-gaap	Assets Assets	2007211	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	884195	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	658463	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3542650	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2528459	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	4442606	usd
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	3891361	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	10587	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	75800	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	7041145	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	7055030	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	112100	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	126100	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	17359064	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3442297	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33381760	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17701710	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	79825	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	79825	usd
CY2022Q4	us-gaap	Liabilities Liabilities	33461585	usd
CY2021Q4	us-gaap	Liabilities Liabilities	17781535	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	213227538	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	213227538	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74498761	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74498761	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	21322	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7449	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42919086	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	40663187	usd
CY2022Q4	ENDV	Common Stock Share Subscribed But Unissued Subscription Receivable CommonStockShareSubscribedButUnissuedSubscriptionReceivable	1570	usd
CY2021Q4	ENDV	Common Stock Share Subscribed But Unissued Subscription Receivable CommonStockShareSubscribedButUnissuedSubscriptionReceivable	1570	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75119183	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56443416	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32180319	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15774324	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1281266	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2007211	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	135355	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73105	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	9990	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	14985	usd
CY2022	us-gaap	Gross Profit GrossProfit	125365	usd
CY2021	us-gaap	Gross Profit GrossProfit	58120	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	3389705	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2284667	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3264340	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2226547	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-14026546	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	41057	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	362894	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	22162	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-225268	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1321575	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-941566	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15210495	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-878347	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18474835	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3104894	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18474835	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3104894	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	139206511	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59836620	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-14373786	usd
CY2021	ENDV	Stock Issued During Period Value Connection With Promissory Notes StockIssuedDuringPeriodValueConnectionWithPromissoryNotes	222692	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	126000	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1117900	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	57727	usd
CY2021	ENDV	Stock Issued During Period Value Settlement Of Debt With Former Related Party StockIssuedDuringPeriodValueSettlementOfDebtWithFormerRelatedParty	84697	usd
CY2021	ENDV	Common Shares Issued Pursuant To Consulting Agreement CommonSharesIssuedPursuantToConsultingAgreement	95250	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3104894	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15774324	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15774324	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15774324	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15774324	usd
CY2022	ENDV	Stock Issued During Period Value Connection With Promissory Notes StockIssuedDuringPeriodValueConnectionWithPromissoryNotes	46793	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	142000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	517000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	46147	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1316900	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18474835	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32180319	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-32180319	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-18474835	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-3104894	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	646912	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	648492	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	944	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45000	usd
CY2022	ENDV	Fair Value Of Commitment Shares Issued With Debt FairValueOfCommitmentSharesIssuedWithDebt	7698	usd
CY2021	ENDV	Fair Value Of Commitment Shares Issued With Debt FairValueOfCommitmentSharesIssuedWithDebt	70970	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1311900	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	95250	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	110611	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	144196	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-14026546	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	41057	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	362894	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	22162	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7750	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23850	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	269391	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-42470	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1196394	usd
CY2021	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	733999	usd
CY2022	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	551245	usd
CY2021	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	507244	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-678838	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-986584	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	465000	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	950000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	14000	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	16900	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	142000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	126000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	593000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1059100	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-85838	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72516	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	85936	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13420	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	98	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	85936	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	517000	usd
CY2021	us-gaap	Notes Issued1 NotesIssued1	493748	usd
CY2022	ENDV	Conversion Of Preferred C Stock To Common Stock ConversionOfPreferredCStockToCommonStock	255000	usd
CY2021	ENDV	Conversion Of Preferred C Stock To Common Stock ConversionOfPreferredCStockToCommonStock	33333	usd
CY2022	ENDV	Original Debt Discount On Convertible Notes OriginalDebtDiscountOnConvertibleNotes	45398	usd
CY2021	ENDV	Issuance Of Common Stock To Settle Debt IssuanceOfCommonStockToSettleDebt	202697	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75100000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-700000	usd
CY2022Q4	ENDV	Working Capital Deficiency WorkingCapitalDeficiency	33400000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	600000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zlN9gfygGlNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zRY86fpiG9c4">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services and in connection with notes payable agreements, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	7039832	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	6442035	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1355310243	shares
CY2022	ENDV	Accrued Interest AccruedInterest	632789106	shares
CY2022Q4	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	17359064	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17359064	usd
CY2021Q4	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	3442297	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3442297	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4202597	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	133386	usd
CY2021	ENDV	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements By Debt Conversion FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlementsByDebtConversion	-585857	usd
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-41057	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3442297	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	109779	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	14026546	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	17359064	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	135355	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73105	usd
CY2021	ENDV	Settlements On Note Payable SettlementsOnNotePayable	-117770	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	135355	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	73105	usd
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	4500000	usd
CY2021Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	4500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3234556	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2587644	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1265444	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1912356	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	646912	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	646912	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	646910	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	618534	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1265444	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	7256930	usd
CY2020Q4	us-gaap	Notes Payable NotesPayable	6835196	usd
CY2022	ENDV	Notes Payable Issued NotesPayableIssued	465000	usd
CY2021	ENDV	Notes Payable Issued NotesPayableIssued	950000	usd
CY2022	ENDV	Settlements On Note Payable SettlementsOnNotePayable	-163826	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	14000	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	16900	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	380272	usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	393596	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	7163832	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	7256930	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	10587	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	75800	usd
CY2022Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	7153245	usd
CY2021Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	7181130	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	112100	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Current And Noncurrent NotesPayableRelatedPartiesCurrentAndNoncurrent	126100	usd
CY2022Q4	ENDV	Notes Payable Issued To Nonrelated Parties NotesPayableIssuedToNonrelatedParties	7041145	usd
CY2021Q4	ENDV	Notes Payable Issued To Nonrelated Parties NotesPayableIssuedToNonrelatedParties	7055030	usd
CY2022Q4	ENDV	Long Term Debt Past Maturity LongTermDebtPastMaturity	6738245	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	415000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	7153245	usd
CY2022	ENDV	Certain Fixed Percentage Of Cash Premium CertainFixedPercentageOfCashPremium	Certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% or 18% premium upon cash redemption by the Company
CY2022Q4	ENDV	Prepayment Penalty PrepaymentPenalty	62800	usd
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	393597	usd
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	100152	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	27461307	shares
CY2021	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2505834	shares
CY2021	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	75175	usd
CY2022	ENDV	Acquisition Payable AcquisitionPayable	79825	usd
CY2021	ENDV	Acquisition Payable AcquisitionPayable	79825	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.18	pure
CY2021Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.12	pure
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.01
CY2022Q3	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	In addition, the Company included a make whole provision, which assures each holder a 15% return on the resale, effectively potentially granting them additional common shares until the holder realizes a 15% return upon resale
CY2022	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	At December 31, 2022, based on the stock price, the value of these shares was in excess of the 15% guaranteed return.
CY2022	ENDV	Stock Issued During Period Fair Values Shares Issued For Services StockIssuedDuringPeriodFairValuesSharesIssuedForServices	66500000	shares
CY2022	ENDV	Stock Issued During Period Fair Values Issued For Services StockIssuedDuringPeriodFairValuesIssuedForServices	1316900	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	501320	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2500350	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.37
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2500350	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	501320	shares
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	33000000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	28000000	usd
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	begin to expire in 2030
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	1	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.017	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.070	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.156	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.010	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.071	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.270	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd

Files In Submission

Name	View Source	Status
0001493152-23-012553-index-headers.html	Edgar Link	pending
0001493152-23-012553-index.html	Edgar Link	pending
0001493152-23-012553.txt	Edgar Link	pending
0001493152-23-012553-xbrl.zip	Edgar Link	pending
endv-20221231.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
endv-20221231_def.xml	Edgar Link	unprocessable
endv-20221231_pre.xml	Edgar Link	unprocessable
endv-20221231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
endv-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENDV
ENDONOVO THERAPEUTICS, INC. Stock $endv

2023 Q2 Form 10-K Financial Statement

#000149315223012553 Filed on April 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENDV ENDONOVO THERAPEUTICS, INC. Stock $endv

2023 Q2 Form 10-K Financial Statement

#000149315223012553 Filed on April 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENDV
ENDONOVO THERAPEUTICS, INC. Stock $endv